The 4th ISCC

December 2, 1999
Nagai Memorial Hall

Program

09:00-09:05

Haruo Sugano (Cancer Chemotherapy Center, Japan)

Welcome and Introduction

I New Strategies for Anticancer Drug Screening

Chairperson: Takashi Tsuruo (University of Tokyo, Japan)

09:05-09:30

John R. Lamb (Fred Hutchinson Cancer Research Center, USA)

HSP90 inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons

09:30-09:55

John N. Weinstein (National Cancer Institute, USA)

Gene expression profiling for cancer chemotherapy: Genomics and bioinformatics

09:55-10:05

Discussion

10:05-10:25

Coffee Break

II Drug Development Targeted at Altered Gene Function in Tumors

Chairpersons:Jean-Pierre Armand (Institut Gustave Roussy, France)
Ryuzo Ueda (Nagoya City Univ. Med. School, Japan)

10:25-10:45

Hirofumi Arakawa (University of Tokyo, Japan)

Identification of target genes for p53, their roles in p53 tumor suppression, and their application for cancer therapy

10:45-11:10

Elisabeth Buchdunger (Novartis Pharma AG, Switzerland)

Inhibition of Abl and PDGF-R protein tyrosine kinases

11:10-11:25

Shin-ichi Nihira (Nippon Roche K.K., Japan)

Development of HER2 specific humanized antibody (Trastuzumab) for the treatment of metastatic breast cancer

11:25-11:50

Randall K. Johnson (SmithKline Beecham Pharmaceuticals, USA)

Inhibition of cell cycle regulation at G2/M phase

11:50-12:00

Discussion

12:00-12:50

Lunch Break

III New Molecular Targets for Anticancer Drug Development

Chairpersons:Susan Arbuck (National Cancer Institute, USA)
Noboru Horikoshi (Cancer Chemotherapy Center, Japan)

12:50-13:15

Julian Adams (LeukoSite, Inc., USA)

Proteasome inhibitors: potent and effective anti-tumor agents

13:15-13:30

Tamio Mizukami (Kyowa Hakko Kogyo Co., Ltd., Japan)

Identification of a novel proteasome inhibitor, UCK14A, by microbial screening using yeast-based assay

13:30-13:45

Kazuyuki Itoh (Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan)

Anti-invasive effects of Rho-kinase (ROCK) inhibitor Y-27632

13:45-14:00

Hidenori Nakajima (Fujisawa Pharmaceutical Co., Ltd., Japan)

FK228, a novel histone deacetylase inhibitor

14:00-14:15

Osamu Nakanishi (Mitsui Pharmaceuticals, Inc., Japan)

A novel synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors

14:15-14:40

Igor B. Roninson (University of Illinois, USA)

Induction of tumor cell senescence by anticancer agents

14:40-14:50

Discussion

14:50-15:10

Coffee Break

IV New Interesting Drugs under Clinical Consideration

Chairpersons:Herbert M. Pinedo (Free University, Netherlands)
Masahiro Fukuoka (Kinki Univ. School of Med., Japan)

15:10-15:40

Jean-Pierre Armand (Institut Gustave Roussy, France)

New anticancer drug in phase I in France

15:40-16:10

Edward A. Sausville (Natonal Cancer Institute, USA)

Flavopiridol and other new anticancer drugs in Phase I/II at the NCI

16:10-16:20

Discussion

V Clinical Evaluation of Non-cytotoxic Agents for Cancer

Chairpersons:Edward A. Sausville (National Cancer Institute, USA)
Yutaka Ariyoshi (Aichi Hospital, Japan)

16:20-16:40

Nagahiro Saijo (National Cancer Center Hospital, Japan)

Could it be possible to obtain licenses of non cytotoxic target-based drugs?

16:40-17:00

Elizabeth A. Eisenhauer (Queen’s University, Canada)

Measure for measure

17:00-17:20

Jaap Verweij (Rotterdam Cancer Institute, Netherlands)

Trial design for new cytostatic agents: Art or artificial?

17:20-17:40

Susan Arbuck (National Cancer Institute, USA)

Molecular targets in early clinical trials

17:40-17:55

Discussion

17:55-18:00

Takashi Tsuruo (Univ. Tokyo, Japan)

Closing Remark

18:00-19:00

Mixer

Page TOP